Have a feature idea you'd love to see implemented?
Let us know!
BEAM Beam Therapeutics Inc
Price (delayed)
$23.3
Market cap
$1.93B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.58
Enterprise value
$1.85B
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a
Highlights
The EPS has surged by 62% year-on-year and by 3.1% since the previous quarter
The net income has surged by 54% year-on-year
BEAM's equity is down by 7% since the previous quarter
Key stats
What are the main financial stats of BEAM
Market
Valuations
Earnings
Shares outstanding
82.81M
Market cap
$1.93B
Enterprise value
$1.85B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.43
Price to sales (P/S)
5.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.3
Revenue
$349.64M
Gross profit
$349.64M
Net income
-$143.59M
EBIT
-$142.19M
EBITDA
-$120.34M
Free cash flow
-$145.37M
Per share
Balance sheet
Liquidity
EPS
-$1.58
EPS diluted
-$1.58
Free cash flow per share
-$1.76
Book value per share
$9.6
Revenue per share
$4.24
TBVPS
$14.21
Total assets
$1.17B
Total liabilities
$380.05M
Debt
$162.07M
Equity
$791.32M
Working capital
$779.29M
Debt to equity
0.2
Current ratio
5.69
Quick ratio
5.61
Net debt/EBITDA
0.62
Margins
Efficiency
Dividend
EBITDA margin
-34.4%
Gross margin
100%
Net margin
-41.1%
Operating margin
-52.2%
Return on assets
-10.9%
Return on equity
-16.2%
Return on invested capital
-14.5%
Return on capital employed
-14.1%
Return on sales
-40.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BEAM stock price
How has the Beam Therapeutics stock price performed over time
Intraday
-8.77%
1 week
-13.96%
1 month
-16.58%
1 year
-8.98%
YTD
-6.05%
QTD
-6.05%
Financial performance
How have Beam Therapeutics's revenue and profit performed over time
Revenue
$349.64M
Gross profit
$349.64M
Operating income
-$182.67M
Net income
-$143.59M
Gross margin
100%
Net margin
-41.1%
Beam Therapeutics's operating margin has surged by 89% YoY
The net margin has soared by 89% YoY
Beam Therapeutics's operating income has surged by 54% YoY
The net income has surged by 54% year-on-year
Growth
What is Beam Therapeutics's growth rate over time
Valuation
What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
2.43
P/S
5.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.3
The EPS has surged by 62% year-on-year and by 3.1% since the previous quarter
The price to book (P/B) is 58% lower than the 5-year quarterly average of 5.8 and 2.8% lower than the last 4 quarters average of 2.5
BEAM's equity is down by 7% since the previous quarter
BEAM's price to sales (P/S) is 100% lower than its 5-year quarterly average of 43856.7 and 10% lower than its last 4 quarters average of 6.1
Efficiency
How efficient is Beam Therapeutics business performance
The return on sales has surged by 89% year-on-year
The ROE has soared by 60% YoY
The company's return on assets has surged by 54% YoY but it fell by 2.8% QoQ
BEAM's ROIC has soared by 51% YoY but it is down by 3.6% QoQ
Dividends
What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BEAM.
Financial health
How did Beam Therapeutics financials performed over time
Beam Therapeutics's total liabilities has decreased by 26% YoY and by 7% QoQ
BEAM's current ratio is up by 21% YoY but it is down by 2.1% QoQ
The debt is 80% less than the equity
The company's debt to equity fell by 9% YoY but it rose by 5% QoQ
BEAM's equity is down by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.